JMP reiterates Oscient's market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating and $3 price target. For the week ended Nov. 25, Factive's prescriptions were 4,544, of which 4,370 were new, representing 0.81% of weekly prescriptions in the quinolone class of antibiotics, compared with 5,527 in the previous week. For the week ended Nov. 25, testosterone gel Testim prescriptions were 4,180 compared with 4,839 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were down 4 cents, or 2.03%, at $1.93 on volume of 365,096 shares versus the three-month running average of 603,809 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.